AbbVie Secures FDA Approval for Juvmo, First D1/D5 Agonist for Parkinson's
AbbVie received FDA approval on Friday for tavapadon, branded as Juvmo, the first selective D1/D5 receptor agonist for adults with Parkinson's disease. The approval validates the company's $8.7 billion acquisition of Cerevel Therapeutics, which closed in August 2024. Juvmo is priced at $4,900 per 30-day supply and is expected to launch in the U.S. next month. While the deal's flagship asset, emraclidine, failed in schizophrenia trials in 2025, Juvmo's success provides a new growth avenue for AbbVie's neuroscience division.
